Seok-Gu Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/323481/publications.pdf

Version: 2024-02-01

166 papers 5,218 citations

38 h-index 62 g-index

171 all docs

171 docs citations

171 times ranked

8561 citing authors

#	Article	IF	CITATIONS
1	Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). Cancer Research and Treatment, 2022, 54, 396-405.	1.3	2
2	Soluble ICAMâ€1 a Pivotal Communicator between Tumors and Macrophages, Promotes Mesenchymal Shift of Glioblastoma. Advanced Science, 2022, 9, e2102768.	5.6	10
3	A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres. Journal of Neuro-Oncology, 2022, 156, 139-151.	1.4	2
4	Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open″abel phase 2 study. Cancer Medicine, 2022, 11, 371-379.	1.3	9
5	Quality of Radiomics Research on Brain Metastasis: A Roadmap to Promote Clinical Translation. Korean Journal of Radiology, 2022, 23, 77.	1.5	15
6	A fully automatic multiparametric radiomics model for differentiation of adult pilocytic astrocytomas from high-grade gliomas. European Radiology, 2022, 32, 4500-4509.	2.3	10
7	Patterns of recurrence according to the extent of resection in patients with IDH–wild-type glioblastoma: a retrospective study. Journal of Neurosurgery, 2022, 137, 533-543.	0.9	4
8	Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. European Radiology, 2022, 32, 8089-8098.	2.3	4
9	Fully automated hybrid approach to predict the <i>IDH </i>) mutation status of gliomas via deep learning and radiomics. Neuro-Oncology, 2021, 23, 304-313.	0.6	114
10	Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology, 2021, 63, 363-372.	1.1	24
11	Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres. Molecules, 2021, 26, 282.	1.7	6
12	Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging. Neuroradiology, 2021, 63, 1811-1822.	1.1	7
13	Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. Journal of Neuroradiology, 2021, 49, 59-59.	0.6	5
14	Sensitive label-free imaging of brain samples using FxClear-based tissue clearing technique. IScience, 2021, 24, 102267.	1.9	2
15	Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study. Neurosurgery, 2021, 89, 257-265.	0.6	11
16	Reply to D'Alessandris et al.: Clear evidence of differences between tumor-resident mesenchymal stemlike cells and bone marrow-derived mesenchymal stem cells. Neuro-Oncology, 2021, 23, 1205-1206.	0.6	1
17	Quality assessment of meningioma radiomics studies: Bridging the gap between exploratory research and clinical applications. European Journal of Radiology, 2021, 138, 109673.	1.2	22
18	Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 282.	3 . 5	19

#	Article	IF	CITATIONS
19	Stereotactic biopsy for adult brainstem lesions: A surgical approach and its diagnostic value according to the 2016 World Health Organization Classification. Cancer Medicine, 2021, 10, 7514-7524.	1.3	10
20	Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle. Frontiers in Oncology, 2021, 11, 736482.	1.3	2
21	A diagnostic tree for differentiation of adult pilocytic astrocytomas from high-grade gliomas. European Journal of Radiology, 2021, 143, 109946.	1.2	5
22	Endoscopic transorbital approach to the insular region: cadaveric feasibility study and clinical application (SevEN-005). Journal of Neurosurgery, 2021, 135, 1164-1172.	0.9	10
23	Influence of the Amount of Fresh Specimen on the Isolation of Tumor Mesenchymal Stem-Like Cells from High-Grade Glioma. Yonsei Medical Journal, 2021, 62, 936.	0.9	2
24	Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant. Journal of Neuro-Oncology, 2021, 155, 267-276.	1.4	10
25	K-RAS Acts as a Critical Regulator of CD44 to Promote the Invasiveness and Stemness of GBM in Response to Ionizing Radiation. International Journal of Molecular Sciences, 2021, 22, 10923.	1.8	9
26	Anterior skull base reconstruction using an anterolateral thigh free flap. Archives of Craniofacial Surgery, 2021, 22, 232-238.	0.4	4
27	A novel paper MAP method for rapid high resolution histological analysis. Scientific Reports, 2021, 11, 23340.	1.6	2
28	Quenching Epigenetic Drug Resistance Using Antihypoxic Microparticles in Glioblastoma Patientâ€Derived Chips. Advanced Healthcare Materials, 2021, , 2102226.	3.9	5
29	Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. Journal of Neurosurgery, 2020, 132, 895-901.	0.9	63
30	Validation and optimization of aÂweb-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. Strahlentherapie Und Onkologie, 2020, 196, 58-69.	1.0	14
31	Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence. World Neurosurgery, 2020, 135, e459-e467.	0.7	3
32	Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status. Neuroradiology, 2020, 62, 319-326.	1.1	28
33	Ambient carbon monoxide exposure and elevated risk of mortality in the glioblastoma patients: A doubleâ€cohort retrospective observational study. Cancer Medicine, 2020, 9, 9018-9026.	1.3	6
34	Silence of Hippo Pathway Associates with Pro-Tumoral Immunosuppression: Potential Therapeutic Target of Glioblastomas. Cells, 2020, 9, 1761.	1.8	7
35	ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. Radiation Oncology, 2020, 15, 184.	1.2	10
36	Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2817-2828.	1.2	18

3

#	Article	IF	Citations
37	Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. European Radiology, 2020, 30, 6475-6484.	2.3	29
38	Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres. Journal of Translational Medicine, 2020, 18, 482.	1.8	4
39	Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axis. Neuro-Oncology, 2020, 22, 1452-1462.	0.6	32
40	Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction. European Radiology, 2020, 30, 3834-3842.	2.3	45
41	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. Scientific Reports, 2020, 10, 10783.	1.6	23
42	Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. Nature Communications, 2020, 11 , 3288.	5.8	44
43	Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Scientific Reports, 2020, 10, 2086.	1.6	44
44	Magnetic resonance imaging–based 3-dimensional fractal dimension and lacunarity analyses may predict the meningioma grade. European Radiology, 2020, 30, 4615-4622.	2.3	19
45	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nature Communications, 2020, 11, 1825.	5 . 8	21
46	Diagnostic challenges of posterior fossa hemangioblastomas: Refining current radiological classification scheme. Scientific Reports, 2020, 10, 6267.	1.6	6
47	Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model. BMC Cancer, 2020, 20, 314.	1.1	74
48	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-NaÃ⁻ve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3287-3295.	3.2	66
49	A Mechanism for microRNA Arm Switching Regulated by Uridylation. Molecular Cell, 2020, 78, 1224-1236.e5.	4.5	52
50	Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone. Journal of Korean Neurosurgical Society, 2020, 63, 26-33.	0.5	18
51	Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. Cancer Research and Treatment, 2020, 52, 1041-1049.	1.3	8
52	Predicting survival using the 2016 World Health Organization classification for anaplastic glioma., 2020, 39, 188-195.		7
53	A pilot study of levetiracetam as a sensitizer of temozolomide for newly diagnosed glioblastoma: A prospective, open-label, phase II study (KBTS-1601 study) Journal of Clinical Oncology, 2020, 38, 2560-2560.	0.8	1
54	Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). Cancer Research and Treatment, 2020, 52, 505-515.	1.3	9

#	Article	IF	CITATIONS
55	SURG-22. PATTERN OF RECURRENCE ALONG EXTENT OF RESECTION IN PATIENTS WITH GLIOBLASTOMA, IDH-WILDTYPE: A RETROSPECTIVE STUDY. Neuro-Oncology, 2020, 22, ii208-ii208.	0.6	0
56	DDRE-08. POTENTIAL THERAPEUTIC EFFECTS OF ETOMOXIR IN COMBINATION WITH TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES. Neuro-Oncology, 2020, 22, ii62-ii63.	0.6	0
57	NIMG-34. QUANTITATIVE MR PARAMETERS FOR THE PREDICTION OF EGFR AMPLIFICATION AND THE TERT PROMOTER MUTATION STATUS OF IDH-WILDTYPE LOWER-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, ii155-ii155.	0.6	0
58	Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. Scientific Reports, 2019, 9, 10555.	1.6	26
59	Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. Biomolecules, 2019, 9, 595.	1.8	22
60	Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. Journal of Neuro-Oncology, 2019, 142, 445-454.	1.4	46
61	Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. European Radiology, 2019, 29, 6643-6652.	2.3	45
62	The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01. Brain Tumor Research and Treatment, 2019, 7, 1.	0.4	19
63	Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1678-1684.	3.3	31
64	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations. Scientific Reports, 2019, 9, 7442.	1.6	43
65	Combined treatment with 2′-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness. Journal of Neuro-Oncology, 2019, 143, 69-77.	1.4	12
66	Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiation Oncology, 2019, 14, 51.	1.2	38
67	EXTH-23. COMBINED EFFECTS OF NICLOSAMIDE AND TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES. Neuro-Oncology, 2019, 21, vi87-vi87.	0.6	0
68	RTHP-05. CONTRIBUTION OF ATM MUTATION TO THE IMPROVED RADIO-SENSITIVITY: RETROSPECTIVE ANALYSIS USING NEXT-GENERATION SEQUENCING DATA. Neuro-Oncology, 2019, 21, vi210-vi211.	0.6	0
69	GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE. Neuro-Oncology Advances, 2019, 1, ii8-ii8.	0.4	0
70	Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma. Clinical Cancer Research, 2019, 25, 2549-2559.	3.2	46
71	Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. Oncolmmunology, 2019, 8, e1525243.	2.1	46
72	Solitary fibrous tumor/hemangiopericytoma: treatment results based on the 2016 WHO classification. Journal of Neurosurgery, 2019, 130, 418-425.	0.9	34

#	Article	IF	Citations
73	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01. Brain Tumor Research and Treatment, 2019, 7, 74.	0.4	7
74	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. Brain Tumor Research and Treatment, 2019, 7, 63.	0.4	8
75	Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. European Journal of Medicinal Chemistry, 2018, 151, 462-481.	2.6	24
76	Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach. European Radiology, 2018, 28, 3832-3839.	2.3	121
77	Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres. Neuro-Oncology, 2018, 20, 954-965.	0.6	57
78	Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation. Oncogene, 2018, 37, 3317-3328.	2.6	38
79	The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model. Scientific Reports, 2018, 8, 4608.	1.6	115
80	MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 87-95.	1.9	18
81	Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of <i>IDH1</i> hutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas. American Journal of Neuroradiology, 2018, 39, 693-698.	1.2	56
82	Amide proton transfer imaging for differentiation of benign and atypical meningiomas. European Radiology, 2018, 28, 331-339.	2.3	43
83	Prediction of $\langle i \rangle$ IDH1 $\langle i \rangle$ -Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas. American Journal of Neuroradiology, 2018, 39, 37-42.	1.2	111
84	SURG-14. ANALYSIS OF TREATMENT RESULTS FOR RECURRENT GLIOBLASTOMA INCLUDING IMMUNE STATUS ALTERATION. Neuro-Oncology, 2018, 20, vi253-vi253.	0.6	0
85	COMP-13. SILENCE OF HIPPO PATHWAY INDUCES PRO-TUMORAL IMMUNITY: NEW THERAPEUTIC TARGET OF GLIOBLASTOMAS. Neuro-Oncology, 2018, 20, vi66-vi66.	0.6	0
86	Association analysis of RTEL1 variants with risk of adult gliomas in a Korean population. PLoS ONE, 2018, 13, e0207660.	1.1	8
87	Pheochromocytoma with Brain Metastasis: A Extremely Rare Case in Worldwide. Brain Tumor Research and Treatment, 2018, 6, 101.	0.4	4
88	Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction. Radiology, 2018, 289, 797-806.	3.6	172
89	Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness. Experimental and Molecular Medicine, 2018, 50, 1-12.	3.2	62
90	Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature, 2018, 560, 243-247.	13.7	460

#	Article	IF	CITATIONS
91	Force-mediated proinvasive matrix remodeling driven by tumor-associated mesenchymal stem-like cells in glioblastoma. BMB Reports, 2018, 51, 182-187.	1.1	20
92	Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. Neuro-Oncology, 2017, 19, now174.	0.6	43
93	Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume. European Radiology, 2017, 27, 3181-3189.	2.3	86
94	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. Medicine (United States), 2017, 96, e7422.	0.4	39
95	Effectiveness of navigation-guided cyst aspiration before resection of large cystic brain tumors: a proof of concept for more radical surgery. Acta Neurochirurgica, 2017, 159, 1947-1954.	0.9	9
96	The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated <i>MGMT </i> Promoter. American Journal of Neuroradiology, 2017, 38, 1528-1535.	1.2	14
97	Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model?. Journal of Neuro-Oncology, 2017, 134, 423-431.	1.4	11
98	Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient. European Radiology, 2017, 27, 1344-1351.	2.3	44
99	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment, 2017, 49, 193-203.	1.3	26
100	IMMU-16. EFFECT OF ANTI-PD-1 THERAPY COMBINATION ON TEMOZOLOMIDE IN MOUSE GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi116-vi116.	0.6	1
101	Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma. PLoS ONE, 2017, 12, e0178881.	1.1	22
102	Spontaneous Acute Subdural Hemorrhage in a Patient with a Tick Borne Bunyavirus-Induced Severe Fever with Thrombocytopenia Syndrome. Korean Journal of Neurotrauma, 2017, 13, 57.	0.2	3
103	Tumor-associated mesenchymal stem-like cells provide extracellular signaling cue for invasiveness of glioblastoma cells. Oncotarget, 2017, 8, 1438-1448.	0.8	32
104	Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients. Cancer Research and Treatment, 2017, 49, 748-758.	1.3	9
105	Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma. Stem Cells International, 2016, 2016, 1-7.	1.2	20
106	Histopathological implications of ventricle wall 5-aminolevulinic acid-induced fluorescence in the absence of tumor involvement on magnetic resonance images. Oncology Reports, 2016, 36, 837-844.	1.2	19
107	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	0.8	35
108	EXTH-28. 5-AMINOLEVULINIC ACID-BASED PHOTODYNAMIC THERAPY OF GLIOBLASTOMA TUMORSPHERE AND ACQUIRED RESISTANCE BY TUMOR MESENCHYMAL STEM-LIKE CELLS. Neuro-Oncology, 2016, 18, vi65-vi65.	0.6	1

#	Article	IF	CITATIONS
109	STMC-13. TUMORSPHERE ISOLATION FROM WHO GRADE IV GLIOMAS ACCORDING TO THE WEIGHT OF FRESH SPECIMENS. Neuro-Oncology, 2016, 18, vi185-vi185.	0.6	0
110	Strategies of Mesenchymal Invasion of Patient-derived Brain Tumors: Microenvironmental Adaptation. Scientific Reports, 2016, 6, 24912.	1.6	62
111	Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. Radiology, 2016, 281, 175-184.	3.6	51
112	Hemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease. Annals of Surgical Oncology, 2016, 23, 954-961.	0.7	13
113	Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient: Feasibility of a patient-derived xenograft. International Journal of Oncology, 2016, 49, 569-578.	1.4	14
114	Terahertz reflectometry imaging for low and high grade gliomas. Scientific Reports, 2016, 6, 36040.	1.6	90
115	Success of tumorsphere isolation from WHO grade IV gliomas does not correlate with the weight of fresh tumor specimens: an immunohistochemical characterization of tumorsphere differentiation. Cancer Cell International, 2016, 16, 75.	1.8	3
116	A polyethylene glycol-based hydrogel as macroporous scaffold for tumorsphere formation of glioblastoma multiforme. Journal of Industrial and Engineering Chemistry, 2016, 39, 10-15.	2.9	20
117	Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments. Cancer Cell International, 2016, 16, 43.	1.8	17
118	PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling. Oncotarget, 2016, 7, 4890-4902.	0.8	9
119	Current and Future Perspectives in Craniosynostosis. Journal of Korean Neurosurgical Society, 2016, 59, 247.	0.5	3
120	ATPS-39COMBINATORY EFFECT OF A NEWLY DESIGNED BIGUANIDE (HL156A) AND TEMOZOLOMIDE AGAINST GLIOBLASTOMA TUMORSPHERE. Neuro-Oncology, 2015, 17, v26.4-v26.	0.6	0
121	Primary Diffuse Leptomeningeal Gliosarcomatosis. Brain Tumor Research and Treatment, 2015, 3, 34.	0.4	3
122	SURG-21HISTOPATHOLOGICAL MEANING OF 5-AMINOLEVULINIC ACID-DERIVED FLUORESCENCE ON THE VENTRICLE WALL WITHOUT INVOLVEMENT OF TUMOR ON MAGNETIC RESONANCE IMAGES. Neuro-Oncology, 2015, 17, v219.1-v219.	0.6	0
123	Potential use of glioblastoma tumorsphere: clinical credentialing. Archives of Pharmacal Research, 2015, 38, 402-407.	2.7	23
124	Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nature Medicine, 2015, 21, 395-400.	15.2	406
125	Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 2015, 33, 2400-2415.	1.4	163
126	Atypical location and clinical behavior of a subset of intracranial germ cell tumors in children younger than 3 years of age. Journal of Neurosurgery: Pediatrics, 2014, 14, 348-355.	0.8	1

#	Article	IF	CITATIONS
127	Study of freshly excised brain tissues using terahertz imaging. Biomedical Optics Express, 2014, 5, 2837.	1.5	145
128	Olfactory changes after endoscopic endonasal transsphenoidal approach for skull base tumors. Laryngoscope, 2014, 124, 2470-2475.	1.1	47
129	Prognostic Value of Glioma Cancer Stem Cell Isolation in Survival of Primary Glioblastoma Patients. Stem Cells International, 2014, 2014, 1-6.	1.2	18
130	Isolation of tumor spheres and mesenchymal stem-like cells from a single primitive neuroectodermal tumor specimen. Child's Nervous System, 2013, 29, 2229-2239.	0.6	14
131	Postoperative nasal symptoms associated with an endoscopic endonasal transsphenoidal approach. European Archives of Oto-Rhino-Laryngology, 2013, 270, 1355-1359.	0.8	36
132	Existence of glioma stroma mesenchymal stemlike cells in Korean glioma specimens. Child's Nervous System, 2013, 29, 549-563.	0.6	26
133	A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer. Cancer Letters, 2013, 337, 49-57.	3.2	10
134	Changes in the biological characteristics of glioma cancer stem cells after serial in vivo subtransplantation. Child's Nervous System, 2013, 29, 55-64.	0.6	10
135	Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Child's Nervous System, 2013, 29, 217-229.	0.6	51
136	Increased in vivo angiogenic effect of glioma stromal mesenchymal stem-like cells on glioma cancer stem cells from patients with glioblastoma. International Journal of Oncology, 2013, 42, 1754-1762.	1.4	30
137	Isolation of mesenchymal stem-like cells in meningioma specimens. International Journal of Oncology, 2013, 43, 1260-1268.	1.4	21
138	Bilateral Nasoseptal Flaps for Endoscopic Endonasal Transsphenoidal Approach. Journal of Craniofacial Surgery, 2013, 24, 1569-1572.	0.3	16
139	Fractionated radiationâ€induced nitric oxide promotes expansion of glioma stemâ€ike cells. Cancer Science, 2013, 104, 1172-1177.	1.7	41
140	Bilateral modified nasoseptal "rescue―flaps in the endoscopic endonasal transsphenoidal approach. Laryngoscope, 2013, 123, 2605-2609.	1,1	47
141	Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma. Journal of Korean Neurosurgical Society, 2013, 54, 489.	0.5	12
142	The Onodi Cell. Otolaryngology - Head and Neck Surgery, 2011, 145, 1040-1042.	1.1	33
143	Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncology Letters, 2011, 2, 115-121.	0.8	36
144	Presence of glioma stroma mesenchymal stem cells in a murine orthotopic glioma model. Child's Nervous System, 2011, 27, 911-922.	0.6	24

#	Article	IF	Citations
145	The Clinical Features of Spinal Leptomeningeal Dissemination from Malignant Gliomas. Journal of Korean Neurosurgical Society, 2011, 49, 334.	0.5	28
146	Isolation and Perivascular Localization of Mesenchymal Stem Cells From Mouse Brain. Neurosurgery, 2010, 67, 711-720.	0.6	75
147	Spinal cord injury in cervical spinal stenosis by minor trauma. World Neurosurgery, 2010, 73, 50-52.	0.7	31
148	Surgical Management and Outcome of Tethered Cord Syndrome in School-Aged Children, Adolescents, and Young Adults. Journal of Korean Neurosurgical Society, 2009, 46, 468.	0.5	27
149	Comparison of the effect of decompressive craniectomy on different neurosurgical diseases. Acta Neurochirurgica, 2009, 151, 21-30.	0.9	45
150	Ruptured right posterior inferior cerebellar artery aneurysm associated with hypoplasia of the right vertebral artery and both internal carotid arteries. British Journal of Neurosurgery, 2009, 23, 551-553.	0.4	5
151	Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. Child's Nervous System, 2008, 24, 293-302.	0.6	49
152	Simple excision and periosteal reattachment for the treatment of calcified cephalhematoma. Journal of Neurosurgery: Pediatrics, 2007, 106, 162-164.	0.8	6
153	Sudden cortical blindness in an adult with moyamoya disease. World Neurosurgery, 2007, 67, 303-307.	1.3	7
154	Surgical results in pediatric moyamoya disease: Angiographic revascularization and the clinical results. Clinical Neurology and Neurosurgery, 2007, 109, 125-131.	0.6	57
155	Pituitary abscess in a pregnant woman. Journal of Clinical Neuroscience, 2007, 14, 1135-1139.	0.8	15
156	Clinical images: Myositis ossificans of the upper extremity. Arthritis and Rheumatism, 2007, 56, 2454-2454.	6.7	2
157	Diagnostic method for differentiating external hydrocephalus from simple subdural hygroma. Journal of Neurosurgery, 2006, 105, 65-70.	0.9	48
158	Multiple stem cell traits of expanded rat bone marrow stromal cells. Experimental Neurology, 2006, 199, 416-426.	2.0	23
159	Merlin inhibits growth hormone-regulated Raf–ERKs pathways by binding to Grb2 protein. Biochemical and Biophysical Research Communications, 2006, 340, 1151-1157.	1.0	30
160	Combined direct anastomosis and encephaloduroarteriogaleosynangiosis using inverted superficial temporal artery–galeal flap and superficial temporal artery–galeal pedicle in adult moyamoya disease. World Neurosurgery, 2006, 66, 389-394.	1.3	24
161	Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncology Reports, 2006, 15, 7.	1.2	18
162	Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy–Walker cyst in a patient with neurocutaneous melanosis. Journal of Neurosurgery, 2006, 104, 444-447.	0.9	26

SEOK-GU KANG

#	Article	IF	CITATIONS
163	Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncology Reports, 2006, 15, 7-13.	1.2	38
164	Clinical and Radiological Prognostic Factors of Anaplastic Oligodendroglioma Treated by Combined Therapy. Neurologia Medico-Chirurgica, 2005, 45, 232-239.	1.0	15
165	Cytotoxicity of rat marrow stromal cells against malignant glioma cells. Child's Nervous System, 2005, 21, 528-538.	0.6	14
166	Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Child's Nervous System, 2004, 20, 154-162.	0.6	13